HRU

Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Retrieved on: 
Friday, October 27, 2023
Survival, Inovalon, Patient, G1 Therapeutics, American Society of Clinical Oncology, Medicare, Thrombocytopenia, EMOL, RESEARCH, Observational study, HRU, PPPM, Aplastic anemia, ESA, Cytopenia, Society, King Fahad Specialist Hospital Dammam, RBC, Risk, G-CSF, Anemia, Therapy, Hospital, PARK, Neutropenia, ASCO, Pharmaceutical industry, Medical imaging, Health insurance, Trilaciclib

1.2% of trilaciclib-treated patients had grade ≥3 HAEs in ≥2 lineages compared to 13.5% of patients in the comparison cohort.

Key Points: 
  • 1.2% of trilaciclib-treated patients had grade ≥3 HAEs in ≥2 lineages compared to 13.5% of patients in the comparison cohort.
  • Assessment of Hospitalizations and Cytopenia Events Among Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Chemotherapy with Trilaciclib (Huang, H. et al.)
  • Burden of Myelosuppression in Extensive-Stage Small-Cell Lung Cancer Patients Receiving Chemotherapy: Retrospective Analysis of Real-World Data from Tennessee Oncology (Blakely, L.J.
  • These findings suggest that how patients present in their initial visits are not necessarily predictive of myelosuppressive events.

Wiwynn Demonstrates Next-Gen Cooling Solutions and Collaborations for AI Era at OCP Global Summit 2023

Retrieved on: 
Friday, October 13, 2023
Partnership, Community, Memorandum of understanding, AI, Open Compute Project, CDU, Carbon, San Jose Convention Center, Immersion, HRU, SAN, OCP, Research, Water, Atmosphere, Renewable energy, Industrial design

"OCP Global Summit 2023 is the leading open-source community for datacenter IT hardware and Wiwynn has been a prominent and dedicated contributor, actively shaping through pioneering designs, collaborations, and insightful whitepapers.

Key Points: 
  • "OCP Global Summit 2023 is the leading open-source community for datacenter IT hardware and Wiwynn has been a prominent and dedicated contributor, actively shaping through pioneering designs, collaborations, and insightful whitepapers.
  • We applaud Wiwynn's unwavering commitment to OCP technology showcased at OCP Global Summit 2023.
  • At the booth, Wiwynn will display one of its headliners, Aqualoop , an OCP ORv3 liquid cooling solution with blind-mate tube features plus advanced cooling management system.
  • Together, we can tackle critical challenges like high-power density, and sustainable datacenters and shape a better future in the AI era."

Chatsworth Products to Exhibit Integrated Cabinet Solution for Direct-on-Chip Dielectric Liquid Cooling at Data Center World 2023

Retrieved on: 
Tuesday, May 2, 2023
HRU, Product management, Expo Hall, Data center, CPI, PDU, Power distribution unit, Carbon, AFCOM, ICT, Artificial intelligence, Cabinet, Ecosystem, Transport, Conference, Renewable energy

SIMI VALLEY, Calif., May 2, 2023 /PRNewswire/ -- Chatsworth Products (CPI), a leading, global manufacturer of products and solutions that power and protect its customers' ever-growing investment in information and communications technology (ICT), will attend and exhibit a full array of data center infrastructure solutions at the AFCOM 2023 Data Center World Conference in Austin, TX, May 8-11, 2023.

Key Points: 
  • Among the products on display in CPI booth 805 will be the company's flagship data center cabinet solution, the ZetaFrame™ Cabinet System, specially outfitted with a dielectric liquid cooling solution from ZutaCore®, whose HyperCool® solution uses a two-phase, waterless, direct-on-chip method of removing heat away from the processors.
  • As workloads cause the processors to heat, the dielectric liquid absorbs the heat causing the liquid to boil and vaporize.
  • Across the data center industry, such advancements are poised to help usher in a more sustainable, environmentally-friendly and carbon neutral technology infrastructure.
  • "We're excited to share this new technology capability with Data Center World attendees," says CPI's Director of Product Management and Hyperscale Business Development, Todd Schneider.

Iceotope collaborates with Intel and HPE to accelerate sustainability and cut power for Edge and Data Center compute requirements by up to 30 Percent

Retrieved on: 
Tuesday, June 28, 2022
Benchmark, Water, Efficiency, Semiconductor, Avnet, LinkedIn, Immersion, Schneider, HRU, Computing, Technology, Carbon, Noise, HPE Discover, Intelligence, Growth, Industry, Gas, Service, Hewlett Packard Enterprise, Atmosphere, Partnership, OEM, Environment, NYSE, Dust, Organization, Intel, Nasdaq, INTC, HPE, Solution, AI, LAS, Maintenance, Service provider, Twitter, Product strategy, Schneider Electric, Conference, Information technology, Online shopping, Renewable energy, Transformer, Heating, ventilation, and air conditioning, Warehouse, Video game console, Software

Ku:l Data Center is the product of a close collaboration between Iceotope, Intel and HPE and promises a faster path to net zero operations by reducing edge and data center energy use by nearly a third.

Key Points: 
  • Ku:l Data Center is the product of a close collaboration between Iceotope, Intel and HPE and promises a faster path to net zero operations by reducing edge and data center energy use by nearly a third.
  • Working together with Intel and HPE, Iceotope benchmarked the power consumption of a sample IT installation being cooled respectively using air and precision immersion liquid cooling.
  • The results show a substantial advantage in favour of liquid cooling, reducing overall power use across IT and cooling infrastructure.
  • Iceotope's Ku:l Data Center demonstrates a very practical response to an urgent need for a paradigm shift in data center design."

Iceotope collaborates with Intel and HPE to accelerate sustainability and cut power for Edge and Data Center compute requirements by up to 30 Percent

Retrieved on: 
Tuesday, June 28, 2022
Benchmark, Water, Efficiency, Semiconductor, Avnet, LinkedIn, Immersion, Schneider, HRU, Computing, Technology, Carbon, Noise, HPE Discover, Intelligence, Growth, Industry, Gas, Service, Hewlett Packard Enterprise, Atmosphere, Partnership, OEM, Environment, NYSE, Dust, Organization, Intel, Nasdaq, INTC, HPE, Solution, AI, LAS, Maintenance, Service provider, Twitter, Product strategy, Schneider Electric, Conference, Information technology, Online shopping, Renewable energy, Transformer, Heating, ventilation, and air conditioning, Warehouse, Video game console, Software

Ku:l Data Center is the product of a close collaboration between Iceotope, Intel and HPE and promises a faster path to net zero operations by reducing edge and data center energy use by nearly a third.

Key Points: 
  • Ku:l Data Center is the product of a close collaboration between Iceotope, Intel and HPE and promises a faster path to net zero operations by reducing edge and data center energy use by nearly a third.
  • Working together with Intel and HPE, Iceotope benchmarked the power consumption of a sample IT installation being cooled respectively using air and precision immersion liquid cooling.
  • The results show a substantial advantage in favour of liquid cooling, reducing overall power use across IT and cooling infrastructure.
  • Iceotope's Ku:l Data Center demonstrates a very practical response to an urgent need for a paradigm shift in data center design."

Analysis Group Is First to Describe Economic Burden for Patients with Acute Suicidal Ideation Tied to Major Depressive Disorder

Retrieved on: 
Tuesday, April 12, 2022
Lists of diseases, Patient, Analysis Group, Major depressive disorder, Behavior, PPPM, Epidemiology, Government, MDD, Janssen, COVID-19, Adult, Population, MDSI, ED, SIB, Research, Principal investigator, Suicide, Janssen Pharmaceuticals, United States Public Health Service, Johnson & Johnson, Health, Carmine, Journal, HRU, The Journal of Clinical Psychiatry, Psychotherapy, Physician, Industry, Risk, Time, Pharmaceutical industry, Hospital, Health insurance

BOSTON , April 12, 2022 /PRNewswire/ -- Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), and the Janssen Pharmaceutical Companies of Johnson & Johnson have authored the first study to describe the economic burden of MDSI, or diagnosed major depressive disorder (MDD) with acute suicidal ideation or behavior (SIB). The study, published in the Journal of Clinical Psychiatry, is timely given the emerging evidence of negative effects of the COVID-19 pandemic on psychological health, and underscores the need for strategies to identify and treat at-risk patients for whom personalized pharmacological and non-pharmacological therapies may prevent a crisis.   

Key Points: 
  • First-of-its-kind study describes costs associated with major depressive disorder with acute suicidal ideation.
  • Inpatient admissions were 158 times higher within 1 month following the event, and 28 times higher within 12 months.
  • Substantial economic burden associated with MDSI persisted in the 12 months following the SIB event.
  • The study, titled "Economic Burden of Commercially Insured Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior in the United States," was published in April by the Journal of Clinical Psychiatry.

Notice from the Office of the Secretary - Ontario Securities Commission

Retrieved on: 
Friday, April 8, 2022
YAU, MICHAEL, Order, The Commission, XIA, LAM, HRU, Online gambling

HRU MORTGAGE INVESTMENT CORPORATION, HRU FINANCIALS LTD., YAU LING (PATRICK) LAM, QINGYANG (MICHAEL) XIA, and ZICHAO (MARSHALL) LIANG,File No.

Key Points: 
  • HRU MORTGAGE INVESTMENT CORPORATION, HRU FINANCIALS LTD., YAU LING (PATRICK) LAM, QINGYANG (MICHAEL) XIA, and ZICHAO (MARSHALL) LIANG,File No.
  • 2022-10
    TORONTO, April 8, 2022 /CNW/ -The Commission issued an Order in the above named matter.
  • A copy of the Order dated April 8, 2022 is available at www.osc.ca

Nevro Announces Two Health Economic Poster Presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2021 Meeting

Retrieved on: 
Tuesday, November 30, 2021
Neurostimulation, RCT, International Society, HRU, Population, International Society for Pharmacoeconomics and Outcomes Research, Arm, Hospital, NYSE, PDN, Randomized controlled trial, Pharmacoeconomics, CMM, SCS, Chronic pain, Diabetic neuropathy, Hyperreflexia, Research, Poster, Length of stay, Hertz, Pharmaceutical industry, Medical imaging, Health insurance

REDWOOD CITY, Calif., Nov. 30, 2021 /PRNewswire/ --Nevro Corp.(NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2021 virtual meeting.

Key Points: 
  • REDWOOD CITY, Calif., Nov. 30, 2021 /PRNewswire/ --Nevro Corp.(NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2021 virtual meeting.
  • ISPOR is a leading professional society for health economics and outcomes research.
  • "We also plan to submit additional findings from the 12-month analysis of the health economic data for publication by the end of this year.
  • The results showed a trend towards a reduction in hospitalization rates for 10 kHz SCS + CMM patients compared to patients treated with CMM alone.

uniQure to Participate in Upcoming Industry Conferences in November

Retrieved on: 
Monday, November 1, 2021
Spinocerebellar ataxia, Fabry disease, Haemophilia, Technology, Temporal lobe, Huntington's disease, CNS, HRU, Patient, NASDAQ, Type III, Investor, Virtual, Mirna, Doctor of Philosophy, Conference, Temporal lobe epilepsy, Q&A, GLOBE, Central nervous system, Liver, ALS, Animal, Pharmaceutical industry

Stifel 2021 Virtual Healthcare Conference, November 15 - 17, 2021

Key Points: 
  • Stifel 2021 Virtual Healthcare Conference, November 15 - 17, 2021
    Members of uniQures management team, including Matt Kapusta , chief executive officer, will participate in virtual one-on-one investor meetings on Wednesday, November 17th.
  • A fireside chat with Mr. Kapusta will take place the same day from 10:40 to 11:10 a.m.
  • The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.
  • uniQure is delivering on the promise of gene therapy single treatments with potentially curative results.

BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization

Retrieved on: 
Wednesday, October 13, 2021
SCM, ASCT, G-CSF, Cell, NDA, Hospital, Length of stay, Stem cell, Transplant, WTP, QALY, FDA, Patient, TASE, Cryopreservation, Trial of the century, Multiple myeloma, Company, GENESIS, HRU, Neutrophil, TEL, Safety, NASDAQ, BioLineRx, Pharmaceutical industry

TEL AVIV, Israel, Oct. 13, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a pharmacoeconomic study evaluating the cost-effectiveness of using investigational drug Motixafortide as a primary stem cell mobilization (SCM) agent on top of granulocyte colony stimulating factor (G-CSF), versus G-CSF alone, in multiple myeloma patients undergoing autologous stem cell transplantation (ASCT). The study was performed by the Global Health Economics and Outcomes Research (HEOR) team of IQVIA, and was a pre-planned study conducted in parallel with the GENESIS Phase 3 trial. These results, together with the highly significant and clinically meaningful data from the GENESIS trial, strongly support the potential use of Motixafortide, on top of G-CSF, as the standard of care in SCM for ASCT.

Key Points: 
  • These cost savings should leave substantial room in the future to optimize our pricing strategy for Motixafortide at product launch and thereafter, if approved.
  • "It is also important to note that fewer administrations and apheresis sessions confer meaningful safety and time benefits to patients.
  • "We believe the data from the GENESIS study, together with the results from this pharmacoeconomic study, set Motixafortide apart from all other mobilization agents either currently available or in development.
  • Motixafortide plus G-CSF was associated with a statistically significant HRU decrease during the autologous stem cell transplantation process compared to standard-of-care G-CSF alone.